This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
In this issue of Neurology®, the results of a 48-week trial of donepezil in patients with mild cognitive impairment (MCI) are reported.1 Although the investigators found a statistically significant effect of donepezil on the modified Alzheimer disease (AD) Assessment Scale–cognitive (ADAS-cog), there was no benefit for donepezil-treated patients on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB).
At face value, the lack of benefit of donepezil on the CDR-SB in patients with MCI over nearly 1 year refutes the presumption that donepezil should be effective in MCI because it was in mild to moderate AD. Two other studies with donepezil reached nearly the same conclusion,2,3 and studies of the other cholinesterase inhibitors rivastigmine4 and galantamine5 also failed to show benefits in MCI.
However, inspection of the data in the current study1 raises questions about the adequacy of the study design. The subjects with MCI in the study did not deteriorate. Over 48 weeks, the CDR-SB ratings dropped only 0.1 point. On the modified …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease
Dr. Marianne de Visser and Dr. Maudy Theunissen